Literature DB >> 29250263

Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient.

Gloria Santangelo1, Alfonso Ielasi1, Pasquale Antonio Scopelliti1, Francesco Pattarino1, Maurizio Tespili1.   

Abstract

A 86-year-old woman with first diagnosed atrial fibrillation (AF) underwent mitral valve annuloplasty 10 years before was admitted to our Unit due to congestive heart failure. Trans-thoracic echocardiogram (TTE) revealed a large fluctuant echogenic mass in the posterior wall of the left atrium. Trans-esophageal echo (TEE) showed the origin of the mass within the left atrial appendage. An adjusted dose of the novel oral anticoagulant (NOAC) apixaban, was prescribed. A complete disappearance was appreciated by examination at 12 weeks after the first drug administration. Although apixaban, resulted superior to warfarin in preventing stroke and thrombo-embolic events in patients with non valvular AF, while causing less bleeding, few data are actually available regarding the efficacy and safety of this drug in left atrium and appendage thrombosis management. Our report shows that this NOAC could be a simple and useful option to manage huge atrial thrombosis in very elderly patients.

Entities:  

Year:  2016        PMID: 29250263      PMCID: PMC5673322          DOI: 10.4022/jafib.1509

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  10 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

2.  Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study.

Authors:  M Kimura; Y Wasaki; H Ogawa; M Nakatsuka; T Wakeyama; T Iwami; K Ono; F Nakao; M Matsuzaki
Journal:  Jpn Circ J       Date:  2001-04

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

4.  Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.

Authors:  Alvaro Avezum; Renato D Lopes; Phillip J Schulte; Fernando Lanas; Bernard J Gersh; Michael Hanna; Prem Pais; Cetin Erol; Rafael Diaz; M Cecilia Bahit; Jozef Bartunek; Raffaele De Caterina; Shinya Goto; Witold Ruzyllo; Jun Zhu; Christopher B Granger; John H Alexander
Journal:  Circulation       Date:  2015-06-23       Impact factor: 29.690

Review 5.  Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.

Authors:  Tatjana S Potpara; Gregory Y H Lip
Journal:  Prog Cardiovasc Dis       Date:  2015-07-07       Impact factor: 8.194

Review 6.  Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?

Authors:  Colleen M Hanley; Peter R Kowey
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

7.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Hans-Christoph Diener; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2015-08-31       Impact factor: 5.214

8.  Resolution of left atrial appendage thrombus with apixaban.

Authors:  Tohru Kawakami; Hiroko Kobayakawa; Hiroyoshi Ohno; Nobukiyo Tanaka; Hiroki Ishihara
Journal:  Thromb J       Date:  2013-12-20

9.  Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.

Authors:  Günter Breithardt; Helmut Baumgartner; Scott D Berkowitz; Anne S Hellkamp; Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf
Journal:  Eur Heart J       Date:  2014-08-22       Impact factor: 29.983

Review 10.  Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.

Authors:  Luigi Di Biase
Journal:  J Am Heart Assoc       Date:  2016-02-18       Impact factor: 5.501

  10 in total
  1 in total

1.  Pulmonary embolism with migrating thrombus through patent foramen ovale: A case for a mixed pharmacological and percutaneous management.

Authors:  Gloria Santangelo; Alfonso Ielasi; Francesco Pattarino; Antonio Tommaso Saino; Pasquale Antonio Scopelliti; Maurizio Tespili
Journal:  J Cardiol Cases       Date:  2018-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.